- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Fate of Antibody-Drug Conjugates in Cancer Cells ; volume:37 ; number:1 ; day:6 ; month:2 ; year:2018 ; pages:1-12 ; date:12.2018
Journal of experimental & clinical cancer research ; 37, Heft 1 (6.2.2018), 1-12, 12.2018
- Keyword
-
Krebs
Onkologie
- Creator
-
Chalouni, Cécile
- Contributor
-
Doll, Sophia
SpringerLink (Online service)
- DOI
-
10.1186/s13046-017-0667-1
- URN
-
urn:nbn:de:1111-201804148988
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chalouni, Cécile
- Doll, Sophia
- SpringerLink (Online service)
Other Objects (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer